{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:53:00Z","timestamp":1787003580420,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Expertise France","award":["19-SB0991"],"award-info":[{"award-number":["19-SB0991"]}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Current WHO-recommended diagnostic tools for tuberculosis infection (TBI) have well-known limitations and viable alternatives are urgently needed. We compared the diagnostic performance and accuracy of the novel QIAreach QuantiFERON-TB assay (QIAreach; index) to the QuantiFERON-TB Gold Plus assay (QFT-Plus; reference). The sample included 261 adults (\u2265\u200918\u2009years) recruited at community-based TB case finding events. Of these, 226 underwent Tuberculin Skin Tests and 200 returned for interpretation (TST; comparator). QIAreach processing and TST reading were completed at lower-level healthcare facilities. We conducted matched-pair comparisons for QIAreach and TST with QFT-Plus, calculated sensitivity, specificity and area under a receiver-operating characteristic curve (AUC), and analyzed concordant-\/discordant-pair interferon-gamma (IFN-\u03b3) levels. QIAreach sensitivity and specificity were 98.5% and 72.3%, respectively, for an AUC of 0.85. TST sensitivity (53.2%) at a 5\u00a0mm induration threshold was significantly below QIAreach, while specificity (82.4%) was statistically equivalent. The corrected mean IFN-\u03b3 level of 0.08 IU\/ml and corresponding empirical threshold (0.05) of false-positive QIAreach results were significantly lower than the manufacturer-recommended QFT-Plus threshold (\u2265\u20090.35 IU\/ml). Despite QIAreach\u2019s higher sensitivity at equivalent specificity to TST, the high number of false positive results and low specificity limit its utility and highlight the continued need to expand the diagnostic toolkit for TBI.<\/jats:p>","DOI":"10.1038\/s41598-023-42515-1","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T10:47:06Z","timestamp":1694688426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparative performance evaluation of QIAreach QuantiFERON-TB and tuberculin skin test for diagnosis of tuberculosis infection in Viet Nam"],"prefix":"10.1038","volume":"13","author":[{"given":"Luan Nguyen Quang","family":"Vo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Thu Phuong","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai Quang","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Thi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Thu","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen Thanh","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa Binh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung Van","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai Thanh","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy Thi Thu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Codlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Forse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan Huy","family":"Mac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhung Viet","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"42515_CR1","unstructured":"World Health Organization. Global Tuberculosis Report 2022 (2022)."},{"key":"42515_CR2","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMra1405427","volume":"372","author":"H Getahun","year":"2015","unstructured":"Getahun, H., Matteelli, A., Chaisson, R. E. & Raviglione, M. Latent mycobacterium tuberculosis infection. N. Engl. J. Med. 372, 2127\u20132135 (2015).","journal-title":"N. Engl. J. Med."},{"key":"42515_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1146\/annurev-publhealth-031912-114431","volume":"34","author":"C Dye","year":"2013","unstructured":"Dye, C., Glaziou, P., Floyd, K. & Raviglione, M. Prospects for tuberculosis elimination. Annu. Rev. Public Health 34, 271\u2013286 (2013).","journal-title":"Annu. Rev. Public Health"},{"key":"42515_CR4","unstructured":"World Health Organization. The End TB Strategy. (2015)."},{"key":"42515_CR5","unstructured":"World Health Organization. Global Tuberculosis Report 2022\u202f: Country profile-Viet Nam. (2022)."},{"key":"42515_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.5588\/ijtld.12.0200","volume":"17","author":"NB Hoa","year":"2013","unstructured":"Hoa, N. B. et al. First national tuberculin survey in Viet Nam: Characteristics and association with tuberculosis prevalence. Int. J. Tuberc. Lung Dis. 17, 738\u2013744 (2013).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"42515_CR7","unstructured":"Office of the Prime Minister. Approval of the National Strategy for TB prevention and control until 2020 with vision to 2030 [vietnamese]. (2014)."},{"key":"42515_CR8","unstructured":"Stop TB Partnership. UN GA HLM on TB Political Declaration: Target for TB Preventive Therapy. 19 (2018)."},{"key":"42515_CR9","unstructured":"Viet Nam National TB Control Programme. NTP Year-end report 2022 [Vietnamese]. (2022)."},{"key":"42515_CR10","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.5588\/ijtld.18.0838","volume":"23","author":"C Mulder","year":"2019","unstructured":"Mulder, C. et al. Tuberculin skin test reaction depends on type of purified protein derivative: Implications for cut-off values. Int. J. Tuberc. Lung Dis. 23, 1327\u20131334 (2019).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"42515_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/CMR.00034-13","volume":"27","author":"M Pai","year":"2014","unstructured":"Pai, M. et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin. Microbiol. Rev. 27, 3\u201320 (2014).","journal-title":"Clin. Microbiol. Rev."},{"key":"42515_CR12","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.lpm.2017.01.015","volume":"46","author":"A Matteelli","year":"2017","unstructured":"Matteelli, A. et al. Tuberculosis elimination and the challenge of latent tuberculosis. Press. Med. 46, e13\u2013e21 (2017).","journal-title":"Press. Med."},{"key":"42515_CR13","doi-asserted-by":"crossref","unstructured":"Faust, L., Ruhwald, M., Schumacher, S. & Pai, M. How are high burden countries implementing policies and tools for latent tuberculosis infection? A survey of current practices and barriers. Heal. Sci. Rep. 3, (2020).","DOI":"10.1002\/hsr2.158"},{"key":"42515_CR14","doi-asserted-by":"crossref","unstructured":"Hamada, Y. et al. Framework for the evaluation of new tests for tuberculosis infection. Eur. Respir. J. 58, (2021).","DOI":"10.1183\/13993003.04078-2020"},{"key":"42515_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"M Pai","year":"2008","unstructured":"Pai, M., Zwerling, A. & Menzies, D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: An update. Ann. Intern. Med. 149, 177\u2013184 (2008).","journal-title":"Ann. Intern. Med."},{"key":"42515_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-017-2301-4","volume":"17","author":"P Auguste","year":"2017","unstructured":"Auguste, P. et al. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: Systematic review and meta-analysis. BMC Infect. Dis. 17, 1\u201313 (2017).","journal-title":"BMC Infect. Dis."},{"key":"42515_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jinf.2019.08.018","volume":"79","author":"G Sotgiu","year":"2019","unstructured":"Sotgiu, G. et al. QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: A systematic review and meta-analysis. J. Infect. 79, 444\u2013453 (2019).","journal-title":"J. Infect."},{"key":"42515_CR18","unstructured":"World Health Organization. WHO Operational Handbooks, Module 1\u202f: Prevention, Annex 6. Answers to frequently asked questions on IGRAs. WHO TB Knowledge Sharing Platform https:\/\/tbksp.org\/en\/node\/666 (2021)."},{"key":"42515_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","volume":"12","author":"MX Rangaka","year":"2012","unstructured":"Rangaka, M. X. et al. Predictive value of interferon-\u03b3 release assays for incident active tuberculosis: A systematic review and meta-analysis. Lancet Infect. Dis. 12, 45\u201355 (2012).","journal-title":"Lancet Infect. Dis."},{"key":"42515_CR20","unstructured":"Abubakar, I. et al. Articles Prognostic value of interferon-\u03b3 release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB ): A prospective cohort study. 3099, 1\u201311 (2018)."},{"key":"42515_CR21","unstructured":"QIAGEN. QIAreach\u00ae QuantiFERON\u00ae\u2013TB Test Quick Reference Guide. www.qiagen.com (2021)."},{"key":"42515_CR22","unstructured":"Ministry of Health. Decision on the promulgation of the Guidelines on the detection and treatment of Latent TB Infection [vietnamese]. (2020)."},{"key":"42515_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1183\/13993003.02563-2021","volume":"59","author":"F Saluzzo","year":"2022","unstructured":"Saluzzo, F., Mantegani, P., de Chaurand, V. P. & Cirillo, D. M. QIAreach QuantiFERON-TB for the diagnosis of Mycobacterium tuberculosis infection. Eur. Respir. J. 59, 6\u20139 (2022).","journal-title":"Eur. Respir. J."},{"key":"42515_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.pulmoe.2021.07.003","volume":"28","author":"K Fukushima","year":"2022","unstructured":"Fukushima, K. et al. First clinical evaluation of the QIAreachTM QuantiFERON-TB for tuberculosis infection and active pulmonary disease. Pulmonology 28, 6\u201312 (2022).","journal-title":"Pulmonology"},{"key":"42515_CR25","first-page":"917","volume":"25","author":"F Stieber","year":"2021","unstructured":"Stieber, F. et al. Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis. 25, 917\u2013922 (2021).","journal-title":"Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis."},{"key":"42515_CR26","first-page":"207","volume":"30","author":"F Li","year":"2018","unstructured":"Li, F. & He, H. Assessing the accuracy of diagnostic tests. Shanghai Arch. Psychiatry 30, 207\u2013212 (2018).","journal-title":"Shanghai Arch. Psychiatry"},{"key":"42515_CR27","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/S1473-3099(20)30276-0","volume":"20","author":"G Zhou","year":"2020","unstructured":"Zhou, G. et al. Interferon-\u03b3 release assays or tuberculin skin test for detection and management of latent tuberculosis infection: A systematic review and meta-analysis. Lancet Infect. Dis. 20, 1457\u20131469 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"42515_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0169539","volume":"12","author":"SK Sharma","year":"2017","unstructured":"Sharma, S. K., Vashishtha, R., Chauhan, L. S., Sreenivas, V. & Seth, D. Comparison of TST and IGRA in diagnosis of latent tuberculosis infection in a high TB-burden setting. PLoS ONE 12, 1\u201311 (2017).","journal-title":"PLoS ONE"},{"key":"42515_CR29","unstructured":"Viet Nam National TB Control Programme. NTP Year-End Report 2021 [Vietnamese]. (2021)."},{"key":"42515_CR30","unstructured":"Viet Nam National TB Control Programme. Amendment of the positive threshold of Mantoux test for Latent Tuberculosis diagnostic according to the manufacturer\u2019s instructions [Vietnamese]. (2022)."},{"key":"42515_CR31","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.ijid.2022.02.047","volume":"124","author":"D Goletti","year":"2022","unstructured":"Goletti, D., Delogu, G., Matteelli, A. & Migliori, G. B. The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. Int. J. Infect. Dis. 124, S12\u2013S19 (2022).","journal-title":"Int. J. Infect. Dis."},{"key":"42515_CR32","unstructured":"US Centers for Disease Control and Prevention. TST vs IGRAs. https:\/\/www.cdc.gov\/tb\/webcourses\/course\/chapter3\/3_testing_for_tb_disease_and_ltbi_3_mantoux_tuberculin_skin_test_tst_vs_igras.html (2022)."},{"key":"42515_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.02006","volume":"11","author":"C Carranza","year":"2020","unstructured":"Carranza, C., Pedraza-Sanchez, S., de Oyarzabal-Mendez, E. & Torres, M. Diagnosis for latent tuberculosis infection: New alternatives. Front. Immunol. 11, 1\u201313 (2020).","journal-title":"Front. Immunol."},{"key":"42515_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.pulmoe.2021.07.010","volume":"28","author":"P Miotto","year":"2022","unstructured":"Miotto, P., Goletti, D. & Petrone, L. Making IGRA testing easier: First performance report of QIAreach QFT for tuberculosis infection diagnosis. Pulmonology 28, 4\u20135 (2022).","journal-title":"Pulmonology"},{"key":"42515_CR35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jiac.2019.02.018","volume":"25","author":"H Igari","year":"2019","unstructured":"Igari, H. et al. Positivity rate of interferon-\u03b3 release assays for estimating the prevalence of latent tuberculosis infection in renal transplant recipients in Japan. J. Infect. Chemother. 25, 537\u2013542 (2019).","journal-title":"J. Infect. Chemother."},{"key":"42515_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph192013529","volume":"19","author":"P Yoopetch","year":"2022","unstructured":"Yoopetch, P. et al. Economic evaluation of screening strategy for latent tuberculosis infection (LTBI) in contacts of tuberculosis patients: Systematic review and quality assessment. Int. J. Environ. Res. Public Health 19, 1\u201312 (2022).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"42515_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12890-022-02149-x","volume":"22","author":"J Mahon","year":"2022","unstructured":"Mahon, J. et al. A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations. BMC Pulm. Med. 22, 1\u201310 (2022).","journal-title":"BMC Pulm. Med."},{"key":"42515_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.36497\/jri.v42i1.282","volume":"42","author":"R Hardian","year":"2022","unstructured":"Hardian, R., Reviono, R., Kusumo, H. & Sutanto, Y. S. Concordance of TST and QFT-Plus, sensitivity and specificity of TST and QFT-Plus in detection of LTBI in MDR TB contact. J. Respirologi Indones. 42, 9\u201317 (2022).","journal-title":"J. Respirologi Indones."},{"key":"42515_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/tropicalmed5040185","volume":"5","author":"LH Nguyen","year":"2020","unstructured":"Nguyen, L. H. et al. An evaluation of programmatic community-based chest X-ray screening for tuberculosis in Ho Chi Minh City Vietnam. Trop. Med. Infect. Dis. 5, 185 (2020).","journal-title":"Trop. Med. Infect. Dis."},{"key":"42515_CR40","first-page":"1","volume":"221","author":"TH Mac","year":"2020","unstructured":"Mac, T. H. et al. Optimizing active tuberculosis case finding\u202f: Evaluating the impact of community referral for Chest X-ray screening and Xpert testing on case notifications in two cities in Viet Nam. Trop. Med. Infect. Dis. 221, 1\u201315 (2020).","journal-title":"Trop. Med. Infect. Dis."},{"key":"42515_CR41","doi-asserted-by":"publisher","first-page":"2102563","DOI":"10.1183\/13993003.02563-2021","volume":"59","author":"F Saluzzo","year":"2022","unstructured":"Saluzzo, F., Mantegani, P., Poletti de Chaurand, V. & Cirillo, D. M. QIAreach QuantiFERON-TB for the diagnosis of Mycobacterium tuberculosis infection. Eur. Respir. J. 59, 2102563 (2022).","journal-title":"Eur. Respir. J."},{"key":"42515_CR42","unstructured":"QIAGEN. QIAreach\u00ae QuantiFERON\u00ae-TB Test Instructions for Use (2021)."},{"key":"42515_CR43","unstructured":"QIAGEN. QIAreach\u00ae eHub User Manual. 1\u201340 (2021)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42515-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42515-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42515-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T04:20:32Z","timestamp":1700281232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42515-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["42515"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-42515-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"19 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.N.Q.V., A.J.C., R.J.F., T.T.T.D., N.V.N., H.B.N., and T.H.M. received funding from Expertise France. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15209"}}